Project Grant R21AI193883
- The National Institutes of Health (NIH) awarded a $156,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Georgetown University on August 11, 2025. The project, titled "Development of a Multiomic Biodosimetry Panel for Use During Sepsis and Antibiotic Treatment", aims to develop a novel panel of metabolomic and gene expression biomarkers to rapidly screen and provide accurate dose reconstruction for individuals exposed to ionizing radiation. This panel will...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) provides $149,008 to evaluate the use of PEG-BPEI as a potential mitigator against gastrointestinal acute radiation syndrome (GI-ARS). The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. will develop a murine model of partial body irradiation to study the effects of radiation on the GI tract while minimizing systemic...
- This Project Grant award of $153,000.00, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), focuses on investigating potential radiomitigating strategies for gastrointestinal acute radiation syndrome (GI-ARS). The research project has two novel approaches: 1) Evaluating the mitigating effects of dietary methionine restriction on GI-ARS following radiation exposure, and 2) Exploring a second approach outlined in Aim 2 (details not...
- This $164,500 Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports the development and validation of human normal tissue patient-derived organoids (NT-PDOs) for pre-screening new candidate gastrointestinal (GI) radiation countermeasure drugs. The goal is to create an extracorporeal model based on healthy human GI tissue that can accurately assess the efficacy and safety of radiation mitigators, addressing limitations of...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $155,000 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the mitochondrial serine/threonine phosphatase PGAM5 as a potential target for mitigating gastrointestinal acute radiation syndrome (GI-ARS). The research aims to examine the role of PGAM5 in radiation-induced oxidative stress and modulation of Wnt/β-catenin...
- The U.S. Department of Health and Human Services National Institutes of Health (NIH) awarded a $156,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Medical College of Wisconsin, Inc. The overall objective of this 2-year project, from August 1, 2025 to July 31, 2027, is to develop a panel of biomarkers that can discriminate between exposure of upper- and lower-body organs to radiation and predict health outcomes. The research aims to identify organ-specific...
- This $167,500 Project Grant awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel and effective medical countermeasure to treat the gastrointestinal acute radiation syndrome (GI-ARS). The grant recipient, The Feinstein Institutes For Medical Research, will conduct research to demonstrate that MSP68 can mitigate GI-ARS by promoting the recovery of gut stem cells and reducing intestinal damage...
- The Project Grant titled "Engineered Microbes to Mitigate Intestinal Radiation Damage" was awarded by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $160,125 award to Baylor College of Medicine aims to explore the use of the microbiome to deliver growth factors that promote survival and proliferation of radioresistant intestinal stem cells. The objective is to assess a genetically...
- The National Institutes of Health (NIH) awarded a $570,849 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Georgetown University to develop predictive biomarker panels to assess the risk of delayed lung and kidney injuries resulting from acute radiation exposure. The goal is to expand existing "LungWatch" and "KidneyWatch" biomarker panels for use in diverse civilian populations and incorporate them into prototype devices. Georgetown...
- This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) is for the development of a thrombopoietin mimetic (TPOM) as a medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS). The total award amount is $593,823 with a project period from December 2024 to November 2029. The primary awardee, Albert Einstein College of Medicine, is collaborating with The Henry M. Jackson Foundation for the...
This Project Grant award, totaling $156,000.00, was provided by the Office of the Director of the U.S. Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The project aims to develop a novel, dual-specimen biomarker strategy to improve early detection of gastrointestinal acute radiation syndrome (GI-ARS) using angiotensin-converting enzyme 2 (ACE2) as an early tissue-specific biomarker. The study, conducted by Georgetown University, will evaluate the temporal dynamics and dose-dependent changes in fecal and serum ACE2 levels following radiation exposure in mouse models to provide a more comprehensive measure of GI injury and enable earlier prediction of GI-ARS within the critical 24-48 hour post-exposure window. This research is expected to yield a sensitive and minimally invasive biomarker approach for improved clinical intervention and better survival outcomes for GI-ARS. The award period runs from August 7, 2025, to July 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $156.0k | 8/7/25 |